Neal X. Rosen

This study shows that coexisting PTEN and PIK3CA mutations in endometrial cancers hyperactivate mTORC1, making them sensitive to mTORC1 inhibitors but not PI3K or AKT inhibitors.

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

The paper shows that diet-induced insulin resistance results from increased PTEN expression, which inhibits PI3K signaling, and that PTEN and mTORC1 inhibitors can reverse this effect.

This study shows that BRAFV600E mutations inhibit cell migration and invasion through feedback inhibition of RAC1, requiring secondary mutations to overcome this block and enable tumorigenesis.

The paper develops patient-derived organoids and mouse models of appendiceal cancer to identify phenotypic changes and drug targets in peritoneal metastasis.